Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BGV1

Financiado

Cerrado

New vaccine for a paradigm shift in Brucellosis one of the world s most widespr...

New vaccine for a paradigm shift in Brucellosis one of the world s most widespread zoonotic diseases affecting humans Brucellosis is the world’s most widespread zoonotic disease. It is a global problem but most severely affects poor livestock keepers in the developing world because of its impacts on human and animal health and livelihoods. Brucel... ver más

28/02/2023

BRUCELLA GREEN VAC

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

BRUCELLA GREEN VAC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 1M€

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-02-28

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

BRUCELLA GREEN VAC

1.40M€ | Lider

LA CHERNECA

204.34K€ | Participante

TECNOLOGIA Y VITAMINAS

337.98K€ | Participante

Proyectos interesantes

PID2019-107601RB-C33

Medical Technol...

Agriculture and...

102K€ Cerrado

RTI2018-098658-B-C22

Medical Technol...

Agriculture and...

151K€ Cerrado

AGL2011-30453-C04-03

Medical Technol...

Agriculture and...

157K€ Cerrado

BGV1

Medical Technol...

Agriculture and...

71K€ Cerrado

AGL2009-12674

Medical Technol...

Agriculture and...

103K€ Cerrado

RTI2018-098658-B-C21

Medical Technol...

Agriculture and...

145K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 36 meses Fecha Inicio: 2020-02-20
Fecha Fin: 2023-02-28

Líder del proyecto

BRUCELLA GREEN VAC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 1M€

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Brucellosis is the world’s most widespread zoonotic disease. It is a global problem but most severely affects poor livestock keepers in the developing world because of its impacts on human and animal health and livelihoods. Brucellosis is endemic in most of Asia, Africa and Latin America and is prevalent in the EU Mediterranean regions. Currently vaccines for Brucellosis, around since the 1950s, suffer from serious safety drawbacks mainly due to residual virulence for animals and humans. Combined with rising antibiotic resistance, their use is relatively limited. GreenVac is developing BGV1, the first vaccine in over 60 years against Brucella melitensis in small ruminants that overcomes the main drawbacks of existing vaccines. BGV1 has been designed to a) be avirulent for animals, b) eliminate interference with diagnostic tests after vaccination, c) have low potential transmissibility to humans and, d) be treatable with standard antibiotics. BGV1 is a strong candidate to replace the classic virulent vaccine, exhibiting a safe profile with an enhanced protective efficacy, no residual virulence and minimal serodiagnostic interference. A successful BGV1 EU-project will allow, for the first time, mass vaccination of any animal at any time (including pregnant and lactating animals), which is a radical paradigm shift in Brucellosis control and eradication. The reduction of B. melitensis outbreaks and infection rate in animals will generate €3.81bn in cumulative economic benefits for users by 2029 by evading unnecessary diagnostics costs and losses caused by the infection. It will lead to a lower disease incidence in humans amidst ever rising globalisation and bioterrorism threats to anyone, anywhere. BGV1 will contribute to the objectives of the One Health Initiative: One World, One Health, One Medicine to improve the lives of all species through the integration of human medicine, veterinary medicine and environmental science.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores